Compare Heron Therapeutics Inc (HRTX) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Micron Technology, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while Micron Technology, Inc. trades at $926.17 (market cap $977.44B). The key difference: Micron Technology, Inc. is far larger — about 10687.1× Heron Therapeutics Inc's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | MU | |
|---|---|---|
Market Cap | $91.46M | $977.44B |
Sector | Health | Technology |
52-Week High | $1.96 | $1.21K |
52-Week Low | $0.39 | $104.88 |
Enterprise Value | $189.36M | $957.80B |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Micron (MU) trades at $862.32, down 1.57% with a bearish technical signal, though it remains 30% below its 52-week high. The company reported strong Q3 2025 earnings of $4.78 EPS, beating expectations, with revenue surging to $37.38 billion. Analyst consensus is strongly bullish with an 81.43% buy rating and a $1,550 price target. Recent news highlights memory chip demand driven by AI, though sector-wide bear market concerns persist.
Outlook remains positive due to robust AI-driven memory demand and earnings beats, but risks include cyclical industry volatility and competitive pressures. The stock offers growth potential if it maintains execution amid high expectations, yet investors should monitor sector sentiment and guidance updates for sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
